IP Strategy for Commercial Success
A quarter-day discussion exploring the role of IP in startup and scaleup growth — featuring investor, founder, and IP service perspectives.
IP at Every Stage of Growth
Building IP capability in a startup or scaleup is a different challenge from managing IP in an established organisation. The stakes are high, the resources are constrained, and the decisions made early can shape the value and defensibility of the business for years to come.
This discussion brings together a panel of investors, founders, and IP professionals to explore what good IP strategy looks like at different stages of a company's growth. The format is deliberately conversational — a short panel discussion followed by open dialogue over lunch.
It is designed for in-house IP professionals and those working with startups and scaleups who are curious about the IP dimension. Places are limited to around 40 to keep the conversation genuine.
Event Sponsors
Proud principal sponsor of IP Strategy for Commercial Success.
Proud Sponsor of IP Strategy for Commercial Success.
How the Day Runs
Welcome and Introduction
Opening remarks from IP Insiders.
Panel Discussion
IP strategy in startup and scaleup growth — investor, founder, and IP service perspectives on building IP capability at every stage.
Lunch and Networking
Informal networking over lunch.
Open Discussion
Open conversation on the themes raised in the panel.
Close
Who You'll Hear From
Additional panellists will be announced shortly.
Mark Devlin
CEO
Aculeus Therapeutics
Mark is CEO of the immuno-oncology company Aculeus Therapeutics and has worked in a variety of roles in drug discovery and development in several therapeutic areas including pain, inflammation, autoimmune disease and oncology. In 2020 Mark led the creation of Aculeus Therapeutics and was responsible for in-licensing both the STING and ENPP1 programs. Mark has previously held business-facing roles as COO of the CRC for Cancer Therapeutics and CEO and Managing Director of Oncology One Pty Ltd.
Tim Kay
Frontier Tech Investor
Tin Alley Ventures
Tim is a frontier tech investor at Tin Alley Ventures and has led the firm's investments in i14 (cognitive science-inspired foundational AI) and Kronus (deterministic compute for safety-critical applications). He was previously a management consultant at Boston Consulting Group, working on the energy transition when that was still in vogue. His technical background is in quantum computing, which he studied at UniMelb in Lloyd Hollenberg's group.
Nick Solomon
Lead Product Consultant APAC
Clarivate
Nick Solomon is Lead Product Consultant APAC at Clarivate, where he has spent over a decade helping organisations across the region make strategic use of IP data and analytics. His work focuses on translating IP intelligence into commercial decisions — from competitive landscape analysis to portfolio strategy. He works closely with in-house IP teams to align Clarivate's tools with the practical needs of practitioners.
Helen Mutimer
Head of IP Advisory
FB Rice
Helen Mutimer is Head of IP Advisory at FB Rice. She brings more than two decades of IP experience across both private practice and in-house roles, including over 14 years as Head of IP at Seqirus, a CSL Company, where she managed pharmaceutical IP strategy globally. Her expertise spans IP strategy, freedom to operate, and transaction due diligence across organisations from multinationals to startups. She is a registered Australian and New Zealand patent attorney and was previously registered as a US patent agent.
Damian Slizys
Director of Intellectual Property
Telix Pharmaceuticals
Damian Slizys is Director of Intellectual Property at Telix Pharmaceuticals. He is a registered Trans-Tasman Patent Attorney and holds a PhD in Chemistry.
Registrations Closed
Registrations for this event are now closed. Please contact us at mail@ipinsiders.org.au if you have any questions.
Venue
Woodward Centre
Melbourne Law School
The University of Melbourne